Argenx agreed to acquire Forte Biosciences in a $2.2 billion all-cash deal, taking control of Forte’s anti-CD122 monoclonal antibody FB102 and expanding Argenx’s immunology portfolio. FB102 delivered Phase Ib results in vitiligo, showing a 29.6% mean improvement in facial vitiligo area scoring (FVASI) at week 24 (p=0.020), with statistically significant improvements starting at Day 64. Forte also reported positive Phase Ib data in celiac disease, with Phase II results expected later in 2026. Company statements position FB102 as “pipeline-in-a-product” centered on pathogenic T-cell and NK-cell activity, with potential expansion into additional autoimmune indications such as alopecia areata. The transaction is subject to customary tendering conditions and regulatory clearance, including Hart-Scott-Rodino. For biotech investors, the deal underscores how validated early clinical signals are increasingly translating into large platform acquisitions—particularly in autoimmune immunology where mechanism differentiation and broad patient reach are prized.